NCT03078868 (DWMRI) is a NA clinical trial of Magnetic Resonance Scanner in DWM, sponsored by University of Chicago.

Who is sponsoring NCT03078868?

NCT03078868 is sponsored by University of Chicago.

What drugs are being tested in NCT03078868?

Interventions in NCT03078868: Magnetic Resonance Scanner.

Is NCT03078868 still recruiting?

NCT03078868 is currently terminated. Last updated 18 February 2021.

Are results published for NCT03078868?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2021-02-18 · How we verify

NCT03078868: DWMRI

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Utility of Diffusion-weighted MR Imaging

Terminated NA Results posted Last updated 18 February 2021

What this trial tests

NA trial testing Magnetic Resonance Scanner in DWM in 3 participants. Terminated before completion.

Timeline

15 February 2017

Primary endpoint
18 June 2019

18 June 2019

Quick facts

Lead sponsor	University of Chicago
Phase	NA
Status	Terminated
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	diagnostic
Enrollment	3
Start date	15 February 2017
Primary completion	18 June 2019
Estimated completion	18 June 2019
Sites	1 location across United States

Drugs / interventions tested

Magnetic Resonance Scanner

Conditions studied

DWM — all drugs for DWM →

Sponsor

University of Chicago

Who can join

18 and older, any sex, with DWM. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To determine whether DW-MRI is applicable in the evaluation of post-operative collections, and whether utilization of DW-MRI can enhance application of percutaneous drainage and prevent unnecessary drainage.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other University of Chicago trials

Trials by the same sponsor.

NCT07346196 — A Trial of Locoregionally Advanced Squamous Cell Carcinoma of The Head and Neck · Phase 2 · not yet recruiting
NCT07354100 — Lactulose to Improve Gut Health in Cancer Patients Receiving Immunotherapy · Phase 1, PHASE2 · not yet recruiting
NCT06446661 — Using Text Messages to Improve Oral Chemotherapy for Adolescents and Adults With Acute Lymphoblastic Leukemia · NA · not yet recruiting
NCT07179315 — A Study Comparing Two Immunotherapy Options for Human Papillomavirus Positive HPV-Positive Head and Neck Cancer After Tr · Phase 2 · not yet recruiting
NCT07126561 — Trastuzumab Deruxtecan to Treat HER2 + Newly Diagnosed Metastatic GI Cancers · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03078868 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Chicago
Last refreshed: 18 February 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03078868.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing